A new drug which will help extend the lives of men with prostate cancer has been accepted for use by the NHS in Scotland, in what has been hailed as a ‘landmark decision’.
A Welcome Recommendation
The Institute of Cancer Research (ICR) in London has strongly welcomed the recommendation, which was made by the Scottish Medicines Consortium (SMC), saying that the cancer drug Abiraterone can be used alongside hormone therapy.
Please register or login to comment!
Register now Login